Apotheek Schoonderbuken
ActiveApotheek Schoonderbuken has been active since 2007 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €79k and a net result of €149k. Equity remains stable across the filed fiscal years (±1.7% per year). Its solvency ranks better than 21% of 4107 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).
Checked score
Score 2025
Axes · tick = 2024
Profitability100=
Solvency16▼-1
Growth78=
Stability100
Bankruptcy probability, 12 months
0.5%
Very low
0%0.5%1.5%4%10%≥ 25%
Credit up to €4k at 30 days acceptable
Liquidity short (current ratio 0.9 against 0.88 in 2024), and 89.3% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Eight signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
10.7%
Return on assets
20.2%
Age of the figures
8 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 21% of 4107 sector peers (2025).
NBB · sector comparisonPosition among 4107 sector peers
Solvency
better than 21%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
23 d early
2024
21 d early
2023
5 d late
2022
39 d early
2021
17 d early
2020
31 d early
2019
27 d late
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
12-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€149k▲ 4.4%
2024 · €142k
2018: €96k
2019: €89k
2020: €106k
2021: €110k
2022: €143k
2023: €143k
2024: €142k
2018 → 2025
Working capital
€-56k▲ 0.6%
2024 · €-56k
2018: €166k
2019: €-20k
2020: €10k
2021: €-14k
2022: €-46k
2023: €-59k
2024: €-56k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€74k-€77k▲ 3.6%€77k▲ 0.7%€78k▲ 1.6%€79k▲ 0.7%
Operating result€124k-€156k▲ 26.4%€157k▲ 0.6%€156k▼ 0.5%€164k▲ 4.6%
Net result€110k-€143k▲ 30.0%€143k▼ 0.1%€142k▼ 0.2%€149k▲ 4.4%
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 5% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €737k
Fixed assets
€210k▼ 6.5%
Current assets
€527k▲ 22.3%
Equity and liabilities €737k
Equity
€79k▲ 0.7%
Debt
€658k▲ 14.0%
The debt ratio rises from 88.0% to 89.3%: debt grows faster than equity.
Key figures and ratios
EBITDA
€178k▲
2024 · €173k
Cash flow
€163k▲
2024 · €159k
Solvency
10.7%▼
2024 · 12.0%
Current ratio
0.90▲
2024 · 0.88
Quick ratio
0.54▲
2024 · 0.46
Debt / equity
8.34▲
2024 · 7.36
ROE
188.3%▲
2024 · 181.6%
ROA
20.2%▼
2024 · 21.7%
Interest coverage
12.69▲
2024 · 12.61
Debt
€658k▲
2024 · €577k
Debt ≤ 1 year
€583k▲
2024 · €487k
Debt > 1 year
€70k▼
2024 · €86k
Income taxes
€2k▲
2024 · €2k
Staff costs
€67k▲
2024 · €56k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€655k€737k▲
Fixed assets21/28€225k€210k▼
Intangible fixed assets21€322€0▼
Tangible fixed assets22/27€219k€205k▼
Land and buildings22€206k€195k▼
Plant, machinery and equipment23€11k€9k▼
Furniture and vehicles24€2k€1k▼
Financial fixed assets28€5k€5k=
Current assets29/58€430k€527k▲
Stocks and contracts in progress3€208k€211k▲
Stocks30/36€208k€211k▲
Amounts receivable within one year40/41€95k€134k▲
Trade receivables40€94k€133k▲
Other amounts receivable41€996€951▼
Cash at bank and in hand54/58€121k€175k▲
Deferred charges and accrued income490/1€6k€6k▲
Equity and liabilities
Total equity and liabilities10/49€655k€737k▲
Equity10/15€78k€79k▲
Contributions10/11€62k€62k=
Capital10€62k€62k=
Issued capital100€62k€62k=
Reserves13€17k€17k▲
Non-distributable reserves130/1€6k€6k=
Legal reserve130€6k€6k=
Tax-exempt reserves132€339€339=
Distributable reserves133€10k€11k▲
Profit (loss) carried forward14€0€0=
Amounts payable17/49€577k€658k▲
Amounts payable after more than one year17€86k€70k▼
Financial debts170/4€86k€70k▼
Amounts payable within one year42/48€487k€583k▲
Current portion of amounts payable after more than one year42€16k€16k=
Trade debts44€72k€82k▲
Suppliers440/4€72k€82k▲
Taxes, remuneration and social security45€5k€11k▲
Taxes450/3€226€876▲
Remuneration and social security454/9€4k€11k▲
Other amounts payable47/48€395k€473k▲
Accrued charges and deferred income492/3€4k€5k▲
Income statement
Code20242025
Remuneration, social security and pensions62€56k€67k▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€17k€15k▼
Other operating charges640/8€2k€2k▲
Gross operating margin9900€230k€247k▲
Operating profit (loss)9901€156k€164k▲
Financial income75/76B€1k€816▼
Recurring financial income75€1k€816▼
Financial charges65/66B€14k€14k▲
Recurring financial charges65€14k€14k▲
Profit (loss) for the period before taxes9903€144k€150k▲
Income taxes67/77€2k€2k▲
Profit (loss) for the period9904€142k€149k▲
Profit (loss) for the period to be appropriated9905€142k€149k▲
Appropriation of the result
Profit (loss) to be appropriated9906€142k€149k▲
Transfer to equity691/2€1k€518▼
To other reserves6921€1k€518▼
Profit to be distributed694/7€141k€148k▲
Directors or managers695€141k€148k▲
Social balance
Average headcount (FTE)90871.11.1=
The notes to these accounts (20 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
01-09
State Gazette act
General meeting · Director reappointmentGeneral meeting · Director reappointment · Mandate compensation9 facts ▸
State Gazette act
General meeting · Director reappointment
General meeting · Director reappointment · Mandate compensation9 facts ▸
- General meeting, 2026-01-12
- Director reappointment, Verise BV (niet-statutaire bestuurder)
- Mandate compensation, Verise BV
- Permanent representative, Bram Soetemans
- Board meeting, 2026-01-12
- Director reappointment, Verise BV (gedelegeerd bestuurder)
- Mandate compensation, Verise BV
- Permanent representative, Bram Soetemans
- Permanent representative, Elise Verhaeghe
08-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
2025
31-12
Financial
Highest result since 2018net €149k ▲4.4%
Operating result €164k, net result €149k, both a record.
10-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
05-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 5 days late
2023
22-06
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
14-07
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
30-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
27-08
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema · 27 days late
2019
31-12
Financial
Weakest financial yearnet €89k ▼7.2%
Net result drops to €89k, the lowest in the series; recovery starts the following year.
03-07
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
26-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
04-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 director, no change since 2026
Verise
CurrentManaging director · since 14-01-2026 · Private limited company
14-01-2026
Mandate renewed as Managing director
14-01-2026
Mandate renewed as Non-statutory director
Location & real-estate footprint
Registered office, Scherpenheuvel-Zichem · 1 establishment unit since 2007
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Houwaartstraat 3293270 Scherpenheuvel-ZichemGround area
644 m²
Building footprint
168 m²
Volume, LiDAR
854 m³
Parcel 24098B0428/00K003, Flanders · tallest building 9.7 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
APOTHEEK SCHOONDERBUKEN
since 20072.162.476.329
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24098B0428/00K003 | Flanders | 644 m² | 1 · 168 m² | 9.7 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Ownership & control
1 partyControl over this companysits on this company's board1
1 subsidiary · 1 location
controls
Apotheek SchoonderbukenBE 0888.986.390
Similar companies · same sector, comparable size
PHARMACENTRE
BE 0431.307.134
Wavre · Eq €79k
GENAPPE PHARMA INVEST
BE 0801.925.031
Genappe · Eq €79k
TOELEN APOTEKERS
BE 0437.212.949
Halle · Eq €79k
APOTHEEK DE LINDE
BE 0426.637.474
Retie · Eq €79k
NOVAKA PHARMA
BE 0723.816.176
Nivelles · Eq €79k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 3,218 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPublic limited company
Founded04-04-2007
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
47740Retail trade
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
52310
52320
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
47750Retail sale of cosmetics and toilet articles
Sources
Crossroads Bank for EnterprisesNational Bank · 19 filingsAddress and cadastre registers
Data from official sources, last processed on 12-09-2026. Scores and ratios are computed by Checked and are not a credit decision.